MX2009011002A - Composiciones de proteccion de isquemia/reperfusion y metodos de uso. - Google Patents

Composiciones de proteccion de isquemia/reperfusion y metodos de uso.

Info

Publication number
MX2009011002A
MX2009011002A MX2009011002A MX2009011002A MX2009011002A MX 2009011002 A MX2009011002 A MX 2009011002A MX 2009011002 A MX2009011002 A MX 2009011002A MX 2009011002 A MX2009011002 A MX 2009011002A MX 2009011002 A MX2009011002 A MX 2009011002A
Authority
MX
Mexico
Prior art keywords
ischemia
methods
protection compositions
reperfusion protection
reperfusion
Prior art date
Application number
MX2009011002A
Other languages
English (en)
Spanish (es)
Inventor
Matthew T Andrews
Lester R Drewes
Greg Beilman
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of MX2009011002A publication Critical patent/MX2009011002A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009011002A 2007-04-12 2008-04-11 Composiciones de proteccion de isquemia/reperfusion y metodos de uso. MX2009011002A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91146007P 2007-04-12 2007-04-12
US2632108P 2008-02-05 2008-02-05
PCT/US2008/060100 WO2008128095A1 (en) 2007-04-12 2008-04-11 Ischemia/reperfusion protection compositions and methods of using

Publications (1)

Publication Number Publication Date
MX2009011002A true MX2009011002A (es) 2010-03-15

Family

ID=42269849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011002A MX2009011002A (es) 2007-04-12 2008-04-11 Composiciones de proteccion de isquemia/reperfusion y metodos de uso.

Country Status (12)

Country Link
US (4) US9186340B2 (enExample)
EP (1) EP2146711A4 (enExample)
JP (1) JP2010523714A (enExample)
KR (1) KR20100016456A (enExample)
CN (1) CN101677996A (enExample)
AU (1) AU2008240211A1 (enExample)
BR (1) BRPI0811052A2 (enExample)
CA (1) CA2684213A1 (enExample)
IL (1) IL201406A0 (enExample)
MX (1) MX2009011002A (enExample)
RU (1) RU2459624C2 (enExample)
WO (1) WO2008128095A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186340B2 (en) * 2007-04-12 2015-11-17 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
US9393025B2 (en) * 2010-04-08 2016-07-19 The Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
NL2004569C2 (en) * 2010-04-16 2011-10-18 Angteq B V Compounds for prevention of cell injury.
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
ITMI20120913A1 (it) * 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
EP2976073B1 (en) 2013-03-19 2019-08-28 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
CN104208059A (zh) * 2014-09-05 2014-12-17 中国医学科学院北京协和医院 褪黑素在制备保护吸烟引起血管损伤药物中的应用
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US20170266147A1 (en) * 2016-03-18 2017-09-21 Csilla Ari D'Agostino Methods of increasing latency of anesthetic induction using ketone supplementation
US20190099394A1 (en) * 2016-03-21 2019-04-04 Csilla Ari D'Agostino Methods of improving motor function using ketone supplementation
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
EP3509580A4 (en) * 2016-09-12 2020-05-13 University of South Florida NEUROREGENERATION IMPROVED BY KETONE
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
WO2018167273A1 (en) * 2017-03-16 2018-09-20 Repoceuticals Aps Compositions for retarding the decomposition of melatonin in solution
WO2018187852A1 (en) * 2017-04-12 2018-10-18 Cavaleri Franco Butyrate and beta-hydroxybutyrate compositions and methods of use thereof
WO2018195067A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
US10179095B2 (en) * 2017-06-07 2019-01-15 Dr. Raymond Laboratories Autophage activating resveratrol topical composition for skin improvement and treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
AU2018260927B1 (en) * 2018-05-25 2019-02-21 Graham Sherard Baldwin Methods and compositions for inhibiting a noxious insult
JP2020125254A (ja) * 2019-02-04 2020-08-20 株式会社協和 化粧料、紫外線に対する細胞保護剤、光老化防止剤
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
MX2021014546A (es) * 2019-05-30 2022-01-06 Neuroenergy Ventures Inc Tris (beta-hidroxibutirato) de glicerilo y ataques isquemicos transitorios neuronales.
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
EP4631364A2 (en) * 2022-03-04 2025-10-15 2508 Biosciences LLC Compositions and methods to promote brain health
CN119345192B (zh) * 2024-11-27 2025-10-28 广西医科大学 N-乙酰血清素在防治糖尿病中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298601A (en) * 1972-03-06 1981-11-03 Technutra, S.A. Method and formulations for the treatment of obesity
FR2490631A1 (fr) 1980-09-24 1982-03-26 Roussel Uclaf Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
WO1986000227A1 (en) * 1984-06-22 1986-01-16 Veech Richard L Electrolyte solutions and in vivo use thereof
EP0215138B1 (fr) * 1985-09-06 1991-01-16 Societe Des Produits Nestle S.A. Préservation des tissus vivants
JPS63502274A (ja) * 1985-12-18 1988-09-01 ビ−チ，リチヤ−ド　エル Ｌ↓−乳酸および／またはピルビン酸アニオンを用いた流体式治療法
US5719119A (en) * 1985-12-18 1998-02-17 British Technology Group, Ltd. Parenteral nutrition therapy with amino acids
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5120763A (en) 1986-11-26 1992-06-09 Bar Ilan University Physiologically active and nutritional composition
WO1991002535A1 (en) 1989-08-11 1991-03-07 Basil, Inc. Cancer prevention composition and method
US5257985A (en) * 1989-12-04 1993-11-02 Richard Puhl Multi-chamber intravenous bag apparatus
US5098409A (en) * 1991-01-04 1992-03-24 Massachusetts Institute Of Technology Intravenous bag and monitoring method
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5405333A (en) * 1992-12-28 1995-04-11 Richmond; Frank M. Liquid medicament bag with needleless connector fitting using boat assembly
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5814663A (en) * 1994-08-29 1998-09-29 Wisconsin Alumni Research Foundation Method for maintaining an existing level of body fat
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US5700828A (en) * 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6316038B1 (en) * 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
EP1017379B1 (en) 1997-03-17 2014-12-10 BTG International Limited Therapeutic compositions comprising ketone bodies and precursors thereof
US6262111B1 (en) 1997-05-21 2001-07-17 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US5853388A (en) * 1997-08-21 1998-12-29 Semel; David Intravenous bag with separate compartment
US6107349A (en) 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
AU5787999A (en) * 1998-08-26 2000-03-21 Andrei Zakharovich Afanasiev Method for treating neurodegenerative disorders
DE69935799T2 (de) * 1998-09-15 2007-12-27 Btg International Ltd. Therapeutische zusammenstellungen
US6232354B1 (en) * 1999-01-25 2001-05-15 Seng C. Tan Microcellular polymer foams and method for their production
AU753292B2 (en) * 1999-02-26 2002-10-17 Warner-Lambert Company Llc Bioadhesive antibacterial wound healing composition
US20010051652A1 (en) * 1999-04-28 2001-12-13 Ajinomoto Co., Inc. Method of treating paralysis of the extremities caused by cerebral infarction
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6579852B2 (en) * 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6391345B1 (en) * 2000-05-12 2002-05-21 Tim Heeg Cranberry seed oil, cranberry seed flour and a method for making
DE10028837A1 (de) * 2000-06-15 2001-12-20 Roche Diagnostics Gmbh Verfahren zum Nachweis von Influenza A/B-Viren
US20020077317A1 (en) 2000-12-15 2002-06-20 Das Undurti Narasimha Method of potentating the action of 2-methoxyoestradiol, statins and C-peptide of proinsulin
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
EP1587510A4 (en) * 2003-01-31 2007-08-08 Univ Hong Kong METHOD OF TREATING ISCHEMIC BUST WITH MELATONIN
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US6919483B2 (en) * 2003-05-23 2005-07-19 Mediquest Therapeutics, Inc. Immunomodulation with novel pharmaceutical compositions
US20060280721A1 (en) * 2003-06-03 2006-12-14 The Gov Of Usa Represented By Secretary Of Dpt Of Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
EP1778213B1 (en) 2004-07-16 2017-04-05 BTG International Limited A method for the synthesis of oligomeric compounds
WO2006020179A2 (en) 2004-07-20 2006-02-23 Ketocytonyx Inc. Oligomeric ketone compounds
US20070225252A1 (en) 2004-07-23 2007-09-27 Gross Richard A Ketogenic Saccharides
EP1793813A4 (en) 2004-09-21 2011-05-18 Btg Int Ltd TREATMENT OF HYPERACTIVITY DISORDER WITH DEFICIT ATTENTION (ADHD)
WO2006034361A2 (en) 2004-09-21 2006-03-30 Ketocytonyx Inc. Dopaminergic mimetics
GB0427145D0 (en) * 2004-12-10 2005-01-12 Ketocytonyx Inc Compositions for use in surgery
US9186340B2 (en) * 2007-04-12 2015-11-17 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using

Also Published As

Publication number Publication date
EP2146711A1 (en) 2010-01-27
RU2009141713A (ru) 2011-05-20
BRPI0811052A2 (pt) 2015-01-27
US9186340B2 (en) 2015-11-17
AU2008240211A1 (en) 2008-10-23
RU2459624C2 (ru) 2012-08-27
US20140235690A1 (en) 2014-08-21
CA2684213A1 (en) 2008-10-23
CN101677996A (zh) 2010-03-24
KR20100016456A (ko) 2010-02-12
WO2008128095A1 (en) 2008-10-23
US20160008325A1 (en) 2016-01-14
US8728532B2 (en) 2014-05-20
IL201406A0 (en) 2010-05-31
EP2146711A4 (en) 2011-10-26
US20100197758A1 (en) 2010-08-05
JP2010523714A (ja) 2010-07-15
US20110111049A1 (en) 2011-05-12
US9149450B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
TN2011000482A1 (en) Organic compounds and their uses
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
CR11731A (es) Composiciones y procedimientos para su preparación y uso
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
MY153915A (en) Organic compounds
MY161495A (en) Virus like particle compositions and methods of use
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
TNSN08400A1 (en) Organic compounds and their uses
NO20090596L (no) Antivirale fosfinatforbindelser
PH12015502588B1 (en) 4`-fluoro-2`-methyl substituted nucleoside derivatives
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
HK1217295A1 (zh) 4'-疊氮基，3'-脫氧基-3'-氟取代的核苷衍生物

Legal Events

Date Code Title Description
FA Abandonment or withdrawal